Search Results
Your search for ASCO,ASCO matches 21291 pages
Showing 14901 - 14950
Julie M. Vose, MD, MBA, on Basket Trials
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses this evolution of clinical trials, and using genomic methods to direct therapy.
John G. Gribben, MD, DSc, on Follicular Lymphoma: Still a Role for Transplant?
John G. Gribben, MD, DSc, of Barts Cancer Institute, discusses the pros and cons of both autologous and allogeneic stem cell transplantation in follicular lymphoma, and the challenges of selecting the right patients for these procedures.
Beth M. Faiman, PhD, MSN, CNP, AOCN, on Managing Multiple Myeloma
Beth M. Faiman, PhD, MSN, CNP, AOCN, of the Cleveland Clinic, discusses working with patients with multiple myeloma to minimize the toxicity of their treatment and improve their outcomes.
Julie M. Vose, MD, MBA, on Highlights of Pan Pacific Lymphoma 2016
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses the key presentations at the 2016 Pan Pacific Lymphoma Conference.
Bruce D. Cheson, MD, and Julie M. Vose, MD, MBA, on Staging Lymphoma
Bruce D. Cheson, MD, of Georgetown University Hospital, and Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discuss whether lymphoma should be staged with a positron emission tomography (PET) scan and what follow-up scans are needed.
David G. Maloney, MD, PhD, on Lymphomas: Treatment With CAR T Cells
David G. Maloney, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses the efficacy of chimeric antigen receptor (CAR) T cells for lymphoma and their toxicity.
Stephen M. Ansell, MD, PhD, on Precision Immunotherapy for Refractory Hodgkin Lymphoma
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses the role of checkpoint inhibitors in Hodgkin lymphoma and the efficacy of nivolumab and pembrolizumab.
Susan M. O’Brien, MD, on ALL/Lymphoma: Upfront and Salvage Treatments in Older Patients
Susan M. O’Brien, MD, of the University of California, Irvine, discusses the challenges of treating older patients with acute lymphoblastic leukemia and lymphoma, and the positive results with newer regimens using blinatumomab and inotuzumab.
ASCO Guideline on Potentially Curable Pancreatic Cancer
As reported in the Journal of Clinical Oncology by Alok A. Khorana, MD, of Cleveland Clinic, and colleagues, ASCO has released a clinical practice guideline on the treatment of potentially curable pancreatic cancer.1 The recommendations are based on an expert panel systematic review of the...
Kieron M. Dunleavy, MD, on Lymphomas: Genomics and Genetics
Kieron M. Dunleavy, MD, of the National Cancer Institute, discusses the genomic landscape of aggressive lymphomas and how this is informing therapy decisions.
Andrew D. Zelenetz, MD, on Diffuse Large B-Cell Lymphoma: CHOP-R and EPOCH-R?
Andrew D. Zelenetz, MD, of Memorial Sloan Kettering Cancer Center, discusses the pros and cons of these two regimens, with or without another agent, in diffuse large B-cell lymphoma.
ASCO Guideline on Endocrine Therapy for Metastatic Breast Cancer: Reaffirming Principles for Making Treatment Decisions
The role of endocrine therapy for hormone receptor–positive metastatic breast cancer is well established, and clinicians are strongly encouraged to consider one of several therapeutic options for the majority of patients who present with metastatic disease. The recent ASCO guideline on this topic, ...
ASCO Guideline on Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer
As reported by Hope S. Rugo, MD, of the University of California San Francisco Comprehensive Cancer Center, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on endocrine therapy for hormone receptor–positive metastatic breast cancer.1 The...
Discovery of Fragment Length of Circulating Tumor DNA Might Increase Liquid Biopsy Sensitivity
The liquid biopsy may be a welcome reprieve from typical biopsies. The minimally invasive test could reduce the need for the sometimes painful and risky procedures involved in sampling tumors, particularly those that reside deep within the body. However, thus far, the utility of the test has been...
Five-Year Survival Data: Brentuximab Vedotin May Be Curative in Some Patients With Hodgkin Lymphoma
Five-year survival data published by Chen et al in Blood suggest that the targeted therapy brentuximab vedotin (Adcetris) may be curative in some patients with Hodgkin lymphoma whose disease has persisted despite receiving previous therapies. This multinational phase II study examined brentuximab...
The Metastatic Breast Cancer Project: Direct-to-Patient Research Initiative
A nationwide project is enlisting patients with breast cancer to share their tumor samples and clinical information. Launched in October 2015, the Metastatic Breast Cancer (MBC) Project has enrolled more than 2,000 patients from all 50 states and is yielding information that will be shared with...
Using Social Media to Accelerate Genomic Research
The success of using social media to push forward causes for social good was a driving factor in the launch this past October of the Metastatic Breast Cancer Project (MBC project), which aims to accelerate the understanding of what makes patients with metastatic breast cancer genetically unique....
ASCO Answers Guide to Caregiving
The ASCO Answers: Caregiving guide is designed to help family caregivers better understand their role on the cancer care team. While there is no one way to be a caregiver, people caring for someone with cancer can use this guide to understand how to meet the needs of their loved ones and work...
ASCO and MECC Sponsor International Palliative Care Workshop in Kazakhstan
ASCO recently collaborated with the Middle East Cancer Consortium (MECC) to provide a 3-day International Palliative Care Workshop in Kazakhstan for health-care professionals, advocates, and volunteers in the former capital of Almaty. Dilyara Kaidarova, MD, PhD, Director of the Almaty Oncology...
Sarah S. Donaldson, MD, FASCO, Honored With Inaugural Women Who Conquer Cancer Mentorship Award
Sarah S. Donaldson, MD, FASCO, of Stanford University School of Medicine and Lucile Packard Children’s Hospital, is the recipient of the Inaugural Women Who Conquer Cancer Mentorship Award. Throughout her decades-long career, Dr. Donaldson has mentored countless trainees and young oncologists,...
Leave a Legacy of Hope
By including a planned gift to the Conquer Cancer Foundation in your estate plans, you can help make a dramatic difference for cancer patients years—even decades—into the future. With just one small change to your will or trust, your planned gift of any size will deliver a big impact, and: Your...
ASCO Resolutions Supported by AMA House of Delegates
At the American Medical Association’s (AMA) annual House of Delegates meeting, delegates approved four resolutions submitted by ASCO, demonstrating the entire medical community’s commitment to key cancer care priorities. These resolutions have been incorporated into the AMA’s policy system and will ...
Quick Takes on Promising New Approaches to Treating Breast Cancer
At the 2016 ASCO Annual Meeting, researchers reported encouraging results for several new drugs and treatment strategies for breast cancer. The ASCO Post brings you brief summaries of a select few. Abemaciclib Trial The cyclin-dependent kinase 4/6 (CDK4/6) inhibitor abemaciclib produced responses...
HHS Announces Physician Groups Selected for Initiative Promoting Better Cancer Care
The U.S. Department of Health and Human Services (HHS) has announced that it has selected nearly 200 physician group practices and 17 health insurance companies to participate in a care delivery model that supports and encourages higher quality and more coordinated cancer care. The Medicare arm of...
Brachytherapy Pioneer Haakon Ragde, MD, Chosen as ASTRO 2016 Honorary Member
The American Society for Radiation Oncology (ASTRO) has selected Haakon Ragde, MD, as its 2016 Honorary Member, the highest honor ASTRO confers on distinguished cancer researchers, scientists, and leaders in disciplines other than radiation oncology, radiobiology, or radiation physics. Dr. Ragde...
American Cancer Society Endorses HPV Vaccine Recommendations From CDC ACIP
The American Cancer Society (ACS) has endorsed human papillomavirus (HPV) vaccination recommendations from the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), the principal source of guidance on U.S. immunization policy. The ACS's...
Selected Hematology Abstracts From the 2016 ASCO Annual Meeting
Here are several abstracts selected from the proceedings of the 2016 ASCO Annual Meeting, focusing on clinical trials on therapeutics in different types of leukemia, multiple myeloma, follicular lymphoma, and central nervous system (CNS) lymphoma. For full details of these study abstracts, visit...
Expert Point of View: Patricia A. Ganz, MD & Gregory A. Masters, MD
“This is a tremendous advance. If we had a drug that could achieve these results we would rush to use it. This is also personalized medicine that alerts the health-care team when symptoms need addressing. And it is very important that using the app led to appropriate use of scans and tests, which...
App Triggers Earlier Detection of Relapse, May Help Improve Survival of Patients With Lung Cancer
Web-based applications have invaded mainstream culture and grabbed the attention of multitudes of people around the world. According to a study presented at the 2016 ASCO Annual Meeting, an app may also contribute to extending the lives of people with cancer and, at the same time, reduce...
Benefit Strongly Suggested With Hormonal Maintenance in Low-Grade Serous Carcinoma
In patients with low-grade serous carcinoma, maintenance hormonal therapy reduced the risk of recurrence by 77%, compared with surveillance, in a retrospective cohort from The University of Texas MD Anderson Cancer Center. The study was reported by David Marc Gershenson, MD, at the 2016 ASCO...
PHEREXA: Benefit for Second-Line Pertuzumab Questionable
In the second-line metastatic breast cancer setting, the addition of pertuzumab (Perjeta) to trastuzumab (Herceptin)/capecitabine did not significantly improve progression-free survival, results of the phase III PHEREXA trial showed.1 This is the first randomized trial to evaluate the efficacy of ...
Studies Suggest Bright Future for Combination Immunotherapy in Advanced Melanoma, but Questions Remain
Two studies presented at the 2016 ASCO Annual Meeting focused on the use of combination immunotherapy in the treatment of patients with advanced melanoma. Updated results from the phase III CheckMate 067 trial centered on the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) compared...
CMS Proposal for Part B Drug Payment: A Poorly Conceived Experiment
On March 11, 2016, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule in the Federal Register to test a change in reimbursement for Part B drugs.1 The first phase involves changing the 6% add-on to the average sales price (ASP) used to make drug payments under Part B to...
Charting a New Course at the FDA
In February, after serving for a year as the U.S. Food and Drug Administration’s (FDA’s) Deputy Commissioner for Medical Products and Tobacco, Robert M. Califf, MD, MACC, was named the agency’s Commissioner of Food and Drugs. Prior to his appointment at the FDA, Dr. Califf was the Donald F....
Results of Two Practice-Changing Breast Cancer Trials Upheld
Results of two pivotal breast cancer trials reported at the 2016 ASCO Annual Meeting confirmed the practice-changing findings that resulted from earlier findings. PALOMA-2 The phase III PALOMA-2 trial confirmed results from the smaller, open-label phase II PALOMA-1 trial that led to the U.S. Food...
Stress and Adverse Life Events Unlikely to Cause Breast Cancer
Day-to-day psychological stress and adverse life events are unlikely to increase a woman’s risk of developing breast cancer, according to a new prospective study published by Schoemaker et al in Breast Cancer Research. Women with breast cancer often consider stress as a likely cause of their ...
Swiss Study Examines Cost-Effectiveness of Nivolumab vs Docetaxel in Advanced Nonsquamous NSCLC
Nivolumab, a checkpoint inhibitor approved for patients with squamous and nonsquamous non–small cell lung cancer (NSCLC) in 2015, is not cost-effective when compared to treatment with docetaxel, chemotherapy medication. However, a Swiss analysis showed the cost-effectiveness of nivolumab is...
Patient-Oncologist Difference of Opinion About Advanced Cancer Prognosis Is Common, Study Shows
Misunderstandings about prognosis between patients with advanced cancer and their doctors was common, according to a study by Gramling et al in JAMA Oncology—and the vast majority of patients didn't know that their doctors held different opinions about how long they might live. “We've...
Early Evidence of Anti–PD-1 Activity in Enzalutamide-Resistant Prostate Cancer
Restoring tumor-specific immunity is a treatment strategy that works well in melanoma and lung cancer patients. Now a new study out of the Oregon Health & Science University (OSHU) Knight Cancer Institute is reviving hope that the approach also may help men with life-threatening prostate...
Preclinical Study Shows Target of Trastuzumab, Receptor Protein ErbB2, Needed for Coronary Vasculature Patterning
A receptor protein that is the target of the breast cancer drug trastuzumab (Herceptin) is needed for proper heart blood vessel development, reported researchers from the Perelman School of Medicine at the University of Pennsylvania, Philadelphia. They published their findings this month in a paper ...
PET/MRI: A One-Stop Imaging Test to Detect Prostate Cancer?
A University of Michigan study published by Piert et al in The Journal of Nuclear Medicine reported that the addition of molecular imaging based on F-18-choline positron-emission tomography (PET) improves the identification of significant prostate cancer over multiparametric prostate magnetic...
Juno Therapeutics to Resume JCAR015 Phase II ROCKET Trial After FDA Clinical Hold
Juno Therapeutics, Inc, announced on July 12, 2016, that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the phase II clinical trial of JCAR015 (known as the ROCKET trial) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Under the ...
Opportunistic Salpingectomy for Ovarian Cancer Prevention Adopted Without Adverse Surgical Outcomes
A surgical procedure recommended to reduce the future risk of ovarian cancer has been successfully implemented throughout Kaiser Permanente in Northern California without a change in surgical outcomes, according to research published by Garcia et al in Obstetrics & Gynecology. Previous...
Internationally Renowned Geneticist, Alfred George Knudson, MD, PhD, Dies
Considered a visionary in cancer research, Alfred George Knudson, MD, PhD, was internationally recognized for his “two-hit theory” of cancer causation, which explained the relationship between hereditary and nonhereditary cancer types, predicting the existence of tumor-suppressor genes. ...
New Analysis Evaluates Predictors of Persistent Pain After Breast Cancer Surgery
An analysis led by McMaster University researchers has found that women who undergo armpit lymph node surgery for breast cancer are much more likely to develop chronic pain. Wang et al published their review of studies exploring risk factors for developing chronic pain after breast cancer...
Heart Failure After First Heart Attack Associated With Increased Risk of Cancer
Patients who develop heart failure after their first heart attack have a greater risk of developing cancer when compared to first-time heart attack survivors without heart failure, according to a study published by Hasin et al in the Journal of the American College of Cardiology. Heart failure...
Despite Increasing Global Legalization of Physician-Assisted Suicide, Use Remains Rare
Despite increasing legalization of euthanasia and physician-assisted suicide worldwide, the practices remain relatively rare and, when carried out, are primarily motivated by psychological factors such as loss of autonomy or enjoyment of life, rather than physical pain. A new comprehensive...
Survey Asks Women Whom They Trust Most When Selecting Breast Cancer Surgery and Reviews Postsurgical Satisfaction
A research team led by Rebecca M. Kwait, MD, Breast Health Fellow at The Breast Health Center at Women & Infants Hospital of Rhode Island, recently presented research indicating that when faced with a decision on the type of surgery to have for breast cancer, more women trust their own judgment ...
FDA Approves First HPV Test for Use With SurePath Preservative Fluid
On July 7, the U.S. Food and Drug Administration (FDA) approved the Roche cobas HPV Test as the first test for Human Papilloma Virus (HPV) that can be used with cervical cells obtained for a Papanicolau (Pap) test and collected in SurePath Preservative Fluid. The FDA approves HPV tests to be used...
FDA Advances Precision Medicine Initiative by Issuing Draft Guidances on Next-Generation Sequencing–Based Tests
In support of the President’s Precision Medicine Initiative, on July 6, the U.S. Food and Drug Administration (FDA) issued two draft guidances that, when finalized, will provide a flexible and streamlined approach to the oversight of tests that detect medically important differences in a...
